Registry of treatments for brain arteriovenous malformation in China
Registry of Multimodality Treatment for Brain Arteriovenous Malformation in Mainland China
This study is testing a new treatment plan for brain arteriovenous malformations to see how well it works compared to standard care in patients in China.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 1 Year to 80 Years |
| Sex | All |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT04572568 on ClinicalTrials.gov |
What this trial studies
This is a multi-center, prospective registry study aimed at evaluating the long-term outcomes of brain arteriovenous malformation (AVM) treatments in China. Patients are divided into an experimental group, which receives a standardized multi-disciplinary treatment plan, and a control group, which does not. The study collects comprehensive data on patient demographics, imaging results, and treatment outcomes over a 20-year period. The goal is to establish a standardized diagnosis and treatment process for AVMs based on real-world evidence.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 1-80 years with a confirmed diagnosis of brain AVM who have complete clinical and imaging data.
Not a fit: Patients who have received prior treatment for AVM or have a life expectancy of less than 6 months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols and better outcomes for patients with brain arteriovenous malformations.
How similar studies have performed: Other studies have shown success with multi-disciplinary approaches in treating complex conditions, suggesting potential for positive outcomes in this study as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The diagnosis of AVM was confirmed with digital subtraction angiography (DSA) and/or magnetic resonance imaging(MRI). 2. Patients with complete clinical and imaging data. 3. Patient or patient's legal representative agreed to collection of information for this study and signed informed consent. Exclusion Criteria: 1. Received other treatment (surgery, embolization or SRS)before inclusion; 2. Expected survival time is less than 6 months; 3. Spinal AVMs; 4. Patients missing critical baseline and imaging data.
Where this trial is running
Beijing, Beijing Municipality
- Capital medical university affiliated Beijing Tiantan hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Li Youxiang, MD — Beijing Neurosurgical Institute
- Study coordinator: Chen Yu, MD
- Email: chenyu_tiantan@126.com
- Phone: +8618801239327
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.